Cardlytics filings document a Nasdaq-listed commerce media company's operating results, governance, capital structure, and material events. Form 8-K reports furnish quarterly and annual results, conference-call materials, cost-reduction actions, leadership and compensatory arrangements, and securities information for the company's common stock listed under CDLX.
The filing record also includes disclosure on the completed divestiture of Bridg, including the asset-sale closing and related unaudited pro forma financial statements. Proxy materials cover board matters, shareholder voting items, executive compensation, equity awards, and related governance disclosures for the company’s commerce media business.
Cadre Logistics, Inc. filed a Rule 144 notice reporting planned and recent transfers of Common Stock. The filing lists 6,498 shares of restricted stock vesting on 07/01/2026 (compensation) and two transfers by Amit Gupta of 54,225 shares on 04/02/2026 and 69,833 shares on 04/06/2026, with dollar values shown in the record.
Cardlytics, Inc. reported that Nasdaq notified the company its common stock has closed below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2). The company has until November 30, 2026 to restore a bid price of at least $1.00 for ten consecutive business days or face possible delisting, subject to potential extensions and appeal rights.
To address this and modify its capital structure, Cardlytics approved a 1-for-10 reverse stock split and reduced authorized common shares from 100,000,000 to 10,000,000, effective at 5:00 p.m. Eastern Time on June 5, 2026. Every 10 shares will convert into one share, with no fractional shares issued; cash will be paid instead. Shares outstanding will move from 58,078,634 as of June 1, 2026 to approximately 5,807,863, with proportional adjustments to convertible notes, stock options, restricted stock units, and equity plan reserves. The stock will begin trading on a split-adjusted basis on June 8, 2026.
Cardlytics, Inc. director Srishti A. Gupta reported routine equity compensation activity. On May 20, 2026, Gupta exercised 11,000 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. This increased her directly held common stock to 17,148 shares after the transaction.
On the same date, Gupta received a new grant of 11,000 restricted stock units, each representing a contingent right to one share of Cardlytics common stock or its cash equivalent. According to the terms, these new RSUs vest in full on the one-year anniversary of the grant if she remains a director on that date.
Cardlytics director Francis Jonathan Edward reported routine equity compensation changes. On May 20, 2026, he exercised 11,000 restricted stock units into the same number of common shares and received a new grant of 11,000 RSUs. He now directly holds 26,310 common shares and 11,000 RSUs, which will vest one year after grant if he remains a director.
Cardlytics director Scott A. Hill increased his equity exposure through compensation-related transactions. He exercised 11,000 restricted stock units into 11,000 shares of common stock, and separately received a new grant of 11,000 RSUs that will vest in full after one year of continued board service. Following these moves, he holds 68,748 shares of common stock directly and 11,000 RSUs representing a contingent right to additional shares or their cash equivalent.
Cardlytics, Inc. director Andre J. Fernandez increased his equity-based holdings through routine compensation activity. He exercised 11,000 restricted stock units into 11,000 shares of common stock after they vested in full on the one-year anniversary of their grant. Following this exercise, he directly owns 26,310 shares of common stock.
On the same date, he received a new grant of 11,000 restricted stock units, each representing a right to receive one share of Cardlytics common stock or its cash equivalent at the company’s election. These new RSUs will vest in full on the one-year anniversary of the grant, assuming he continues to serve as a director.
Cardlytics director Liane Hornsey reported routine equity compensation activity. She acquired 11,000 shares of Common Stock through the vesting and conversion of previously granted restricted stock units (RSUs), leaving her with 33,326 Common shares held directly after the transactions.
On the same date, she also received a new grant of 11,000 RSUs, each representing a contingent right to one Cardlytics common share or its cash equivalent, which will vest in full on the one-year anniversary of the grant if she remains a director.
Cardlytics director John L. Klinck Jr. reported equity compensation activity involving the company’s common stock. He acquired 11,000 shares of common stock through the vesting and exercise of previously granted restricted stock units that converted into an equal number of shares.
On the same date, he received a new award of 11,000 restricted stock units, each representing a contingent right to one share of common stock or its cash equivalent. After these transactions, he directly holds 89,593 shares of common stock and 11,000 restricted stock units that are scheduled to vest in full on the one-year anniversary of the grant date, so long as he continues serving as a director.
Cardlytics, Inc. reported the results of its annual stockholder meeting held on May 20, 2026. Of the 55,070,709 shares outstanding as of March 25, 2026, 34,996,216 shares, or 63.54%, were present or represented by proxy.
Stockholders elected three Class II directors—Amit Gupta, Jack Klinck, and Shrishti Gupta—with each receiving over 11 million votes for, and broker non-votes of 21,725,998. They also ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
Investors approved a series of alternate amendments allowing the board, at its option, to implement a reverse stock split of the common stock at a ratio between 1-for-5 and 1-for-15, with a proportionate reduction in authorized shares, any time before the 2027 annual meeting. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.